Schedule 13D ownership disclosure

Aktis Oncology, Inc.

Common Stock, $0.0001 par value per share · CUSIP: 01021M104

Event date: 2026-01-12

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Vida Ventures II, LLCReported CIK 0001776851

    Shares: 5,671,825 · Class: 10.6%

  • Vida Ventures II-A, LLCReported CIK 0001781930

    Shares: 157,387 · Class: 0.3%

  • VV Manager II LLCReported CIK 0001824569

    Shares: 5,829,212 · Class: 10.9%

  • Helen KimReported CIK 0001422772

    Shares: 5,831,315 · Class: 10.9%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001193125-26-013015
Form type
SCHEDULE 13D
Filer
Aktis Oncology, Inc.
CIK
CIK 2035832
Filed
Jan 14, 2026
Reporting period
Jan 12, 2026
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub